ADPT vs. ITOS, REPL, TCRX, AURA, JSPR, TNYA, TRML, LXEO, OCGN, and SLDB
Should you be buying Adaptive Biotechnologies stock or one of its competitors? The main competitors of Adaptive Biotechnologies include iTeos Therapeutics (ITOS), Replimune Group (REPL), TScan Therapeutics (TCRX), Aura Biosciences (AURA), Jasper Therapeutics (JSPR), Tenaya Therapeutics (TNYA), Tourmaline Bio (TRML), Lexeo Therapeutics (LXEO), Ocugen (OCGN), and Solid Biosciences (SLDB). These companies are all part of the "biological products, except diagnostic" industry.
Adaptive Biotechnologies (NASDAQ:ADPT) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.
Adaptive Biotechnologies has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.
iTeos Therapeutics has lower revenue, but higher earnings than Adaptive Biotechnologies. iTeos Therapeutics is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks.
In the previous week, Adaptive Biotechnologies had 6 more articles in the media than iTeos Therapeutics. MarketBeat recorded 6 mentions for Adaptive Biotechnologies and 0 mentions for iTeos Therapeutics. Adaptive Biotechnologies' average media sentiment score of 0.37 beat iTeos Therapeutics' score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.
Adaptive Biotechnologies currently has a consensus price target of $6.80, suggesting a potential upside of 141.99%. iTeos Therapeutics has a consensus price target of $30.33, suggesting a potential upside of 161.27%. Given iTeos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe iTeos Therapeutics is more favorable than Adaptive Biotechnologies.
iTeos Therapeutics has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -132.29%. iTeos Therapeutics' return on equity of -18.40% beat Adaptive Biotechnologies' return on equity.
Adaptive Biotechnologies received 62 more outperform votes than iTeos Therapeutics when rated by MarketBeat users. However, 72.50% of users gave iTeos Therapeutics an outperform vote while only 56.52% of users gave Adaptive Biotechnologies an outperform vote.
99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are held by institutional investors. 5.2% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 10.2% of iTeos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
iTeos Therapeutics beats Adaptive Biotechnologies on 9 of the 17 factors compared between the two stocks.
Get Adaptive Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adaptive Biotechnologies Competitors List
Related Companies and Tools
